KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Karyopharm Therapeutics Inc (KPTI) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock's technical indicators, insider selling trends, and mixed analyst sentiment suggest caution. While the company has positive catalysts such as promising clinical trial results and a recent private placement to enhance liquidity, the financial performance and market sentiment do not currently support a strong buy recommendation.
The MACD histogram is negative and contracting (-0.411), RSI is at 22.231 (neutral zone), and moving averages are converging, showing no clear upward momentum. The stock is trading near its key support level (S1: 5.517), with resistance levels far above the current price. Pre-market price is down 2.15%, indicating weak sentiment.
Phase 3 SENTRY trial showed promising results with significant spleen volume reduction in myelofibrosis patients.
Successful $30 million private placement with RA Capital to support clinical trials and operations.
High gross margin of 95.65% in Q4 2025.
Insider selling has increased significantly (599.43% over the last month).
Mixed analyst sentiment with lowered price targets and reduced probability of FDA approval for key drug Xpovio.
Stock dropped 13% recently due to investor skepticism about FDA approval.
Weak technical indicators and pre-market price decline.
In Q4 2025, revenue increased by 11.58% YoY to $34.08M, but net income remained negative at -$102.2M (up 232.03% YoY). EPS improved to -5.68 (up 54.77% YoY). Gross margin remained high at 95.65%, but the company continues to operate at a loss.
Analyst sentiment is mixed. Baird and H.C. Wainwright recently lowered price targets to $15 and $8, respectively, citing mixed Phase 3 data and reduced probability of FDA approval. Rodman & Renshaw and Cantor Fitzgerald remain optimistic, assigning Buy/Overweight ratings with higher price targets ($28 and $15) based on potential upside from clinical trials and drug pipeline.
